Developer docs
API playgroundTry for free, no card

Search company profiles

Adamis Pharmaceuticals

Full company profile

uuid0005tvd

Namestring
Adamis Pharmaceuticals
Legal namestring
Adamis Pharmaceuticals Corporation
Websiteurl
adamispharmaceuticals.com
Company typeenum
Public
Founded yearint
2006
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
opioid overdose treatment, substance use disorder therapy, naloxone injection products, epinephrine auto-injector, specialty pharmaceuticals
Industry2 codes
1Neurology & Psychiatry (CNS) Pharmaceuticals
CodeHLAIAAAFPrimaryYes
2Pain Management & Anesthesiology Pharmaceuticals
CodeHLAIAAANPrimaryNo
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Revenue model1 record
1Product Sales
TypeOne Time License
Description

Revenue from sale of pharmaceutical products including ZIMHI (naloxone for opioid overdose) and SYMJEPI (epinephrine)

globenewswire.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Operations, Personnel, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Adamis Pharmaceuticals develops, manufactures, and commercializes specialty pharmaceutical products focused on neuro-biotechnology indications. Its marketed portfolio includes ZIMHI, a naloxone injection for opioid overdose reversal, and SYMJEPI, an epinephrine product for severe allergic reactions. The company is also advancing a pipeline of investigational therapies, including DPI-125 for opioid use disorder.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1ZIMHI
CategoryDrug Product
2SYMJEPI
CategoryDrug Product
3DPI-125
CategoryDrug Product
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1DMK Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Adamis Pharmaceuticals announced a merger with DMK Pharmaceuticals, combining capabilities in neuro-biotech product development for opioid overdose and substance use disorders.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adamis Pharmaceuticals

Specialty Pharmaceuticalsadamispharmaceuticals.com

Adamis Pharmaceuticals firmographics

Firmographics
Name
Adamis Pharmaceuticals
Legal name
Adamis Pharmaceuticals Corporation
Website
https://adamispharmaceuticals.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Adamis Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
akta.pro secondary industry
Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

  • Opioid overdose treatment
  • Substance use disorder therapy
  • Naloxone injection products
  • Epinephrine auto-injector
  • Specialty pharmaceuticals

Where Adamis Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Adamis Pharmaceuticals business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

  1. Product Sales: Revenue from sale of pharmaceutical products including ZIMHI (naloxone for opioid overdose) and SYMJEPI (epinephrine)

Distribution channels1 record

Marketing channels1 record

Adamis Pharmaceuticals product offering

Product offering

Core offering

Adamis Pharmaceuticals develops, manufactures, and commercializes specialty pharmaceutical products focused on neuro-biotechnology indications. Its marketed portfolio includes ZIMHI, a naloxone injection for opioid overdose reversal, and SYMJEPI, an epinephrine product for severe allergic reactions. The company is also advancing a pipeline of investigational therapies, including DPI-125 for opioid use disorder.

Differentiator

Problem solved

Functional benefit

Products and services

  • ZIMHI
  • SYMJEPI
  • DPI-125

Companies that use Adamis Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles2 records

Adamis Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Adamis Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • DMK PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2023Adamis Pharmaceuticals announced a merger with DMK Pharmaceuticals, combining capabilities in neuro-biotech product development for opioid overdose and substance use disorders.

Scale indicators3 records

Adamis Pharmaceuticals competitors and assessment

Company assessment

Market position

Customer concentration

Adamis Pharmaceuticals social profiles

Digital presence

Adamis Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adamis Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Adamis Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adamis Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adamis Pharmaceuticals

What does Adamis Pharmaceuticals do?

Adamis Pharmaceuticals develops, manufactures, and commercializes specialty pharmaceutical products focused on neuro-biotechnology indications. Its marketed portfolio includes ZIMHI, a naloxone injection for opioid overdose reversal, and SYMJEPI, an epinephrine product for severe allergic reactions. The company is also advancing a pipeline of investigational therapies, including DPI-125 for opioid use disorder.

Is Adamis Pharmaceuticals a public or private company?

Adamis Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Adamis Pharmaceuticals founded?

Adamis Pharmaceuticals was founded in 2006. It employs 11 to 50 people.

Where is Adamis Pharmaceuticals based?

Adamis Pharmaceuticals is headquartered in San Diego, United States, in the North America region.

How does Adamis Pharmaceuticals make money?

One revenue line is on record: product Sales.

Does Adamis Pharmaceuticals have an API?

No public API is recorded for Adamis Pharmaceuticals.

What industry is Adamis Pharmaceuticals in?

Adamis Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAdamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAdamis Pharmaceuticals reported Q2 2023 results, showing a net loss of $8.6 million and revenues of $0.0 million. The company closed a merger with DMK Pharmaceuticals, and raised about $8.0 million in an August equity offering. Cash and cash equivalents stood at $0.6 million as of June 30, 2023.BenzingaBenzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About YetBenzinga published its weekly Stock Whisper Index for the week of August 5, 2023, highlighting five stocks that are showing unusual investor activity but lack widespread coverage. The featured companies include Tupperware Brands (debt restructuring, short squeeze potential), Adamis Pharmaceuticals (land sale and naloxone collaboration), Trust Stamp (biometric technology expansion to seven additional financial institutions and new AI patent), Traeger (Q2 revenue decline of 14% year-over-year but improved losses and raised full-year guidance), and Driven Brands (Q2 revenue up 19% but lowered guidance with shares down over 40% in the last month). The index is designed to help retail traders identify undervalued and emerging investment opportunities using proprietary data and pattern recognition.YahooAdamis Pharmaceuticals Announces Closing of $8.0 Million Public OfferingAdamis Pharmaceuticals Corporation announced the closing of its public offering of 5,930,000 units, generating approximately $8.0 million in gross proceeds. Each unit was sold at a price of $1.35 and comprises one share of common stock and one warrant to purchase one share of common stock. The offering was conducted with Maxim Group LLC acting as the sole placement agent.GlobeNewswireAdamis Pharmaceuticals Announces Closing of $8.0 Million Public OfferingAdamis Pharmaceuticals Corporation closed a public offering of 5,930,000 units at $1.35 per unit, generating approximately $8.0 million in gross proceeds. Maxim Group LLC acted as the sole placement agent for this transaction, which was filed with the Securities and Exchange Commission. This capital raise supports the commercial-stage biopharmaceutical company's ongoing operations and development programs.TipranksAdamis Pharmaceuticals Announces Closing of $8.0 Million Public OfferingAdamis Pharmaceuticals Corporation announced the closing of its public offering of 5,930,000 units, raising approximately $8.0 million. Each unit was sold at a public offering price of $1.35 and included one share of common stock and one warrant to purchase one share of common stock. The offering was conducted by Maxim Group LLC as the sole placement agent.Stock TitanAdamis Pharmaceuticals Announces Closing of $8.0 Million Public OfferingAdamis Pharmaceuticals Corporation announced the closing of an $8.0 million public offering, selling 5,930,000 units at a price of $1.35 per unit. Maxim Group LLC served as the sole placement agent for this transaction, which was registered with the Securities and Exchange Commission.BenzingaAdamis Pharmaceuticals Announces Closing of $8.0 Million Public OfferingAdamis Pharmaceuticals Corporation closed a public offering of 5,930,000 units at $1.35 per unit, generating approximately $8.0 million in gross proceeds. Maxim Group LLC served as the sole placement agent for this transaction, which was registered with the Securities and Exchange Commission.BenzingaAdamis Pharmaceuticals Stock Soars To More Than Double - What's Going On?Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) shares surged over 176% following the sale of assets from its discontinued pharmacy compounding business to FarmaKeio Pharmacy Network for approximately $2 million, alongside the company's addition to the REG SHO Threshold Security List. The company also announced a merger with DMK Pharmaceuticals Corporation and a 1-for-70 reverse stock split in May, as it pursued strategic alternatives. The research collaboration with Leiden University Medical Center will evaluate the efficacy of Adamis's Zimhi intramuscular naloxone formulation against intranasal naloxone in reversing fentanyl-induced respiratory depression.GlobeNewswireAdamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid ExpertAdamis Pharmaceuticals announced it will fund an unrestricted research grant to Leiden University Medical Center to conduct a clinical study comparing the efficacy of ZIMHI against intranasal naloxone for reversing fentanyl-induced respiratory depression. The study aims to determine if higher blood concentrations of naloxone provided by ZIMHI can more effectively treat overdoses driven by potent opioids like fentanyl. Adamis hopes that positive results from this collaboration with opioid expert Dr. Albert Dahan will lead national health organizations to update emergency protocols to include ZIMHI.BioSpaceAdamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid ExpertAdamis Pharmaceuticals Corporation announced it will fund an unrestricted research grant to the Leiden University Medical Center (LUMC) to support a clinical study on reversing fentanyl overdoses. The study, led by Dr. Albert Dahan, aims to compare the efficacy of Adamis's ZIMHI against standard intranasal naloxone treatments like NARCAN. This initiative follows data indicating that higher doses of naloxone are often required to reverse respiratory depression caused by potent opioids such as fentanyl.